Dallas Diabetes and Endocrine Center

Dallas, Texas 75230

0 studies enrolling now · 25 studies all time

What they study most

Cardiovascular Disease, Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, HIV-1, Hypercholesterolemia, Hyperlipidemia, Impaired Glucose Tolerance, NASH - Nonalcoholic Steatohepatitis, Non Alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease

Studies at this site

• Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects — Running, not enrolling
• Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients — Completed
• Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. — Stopped early
• Multiple Ascending Dose Study of AMG 598 in Adults With Obesity — Completed
• A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. — Completed
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH — Completed
• Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes — Completed
• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes — Completed
• Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c — Stopped early
• Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin — Stopped early
• Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide — Completed
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM — Completed
• AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia — Completed
• Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin — Completed
• Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 — Stopped early
• Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol — Completed
• A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone — Completed
• Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes — Completed
• Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) — Completed
• To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies — Completed
• Obese Patients With or Without Comorbidities (RIO-North America) — Completed